miCure
Therapeutics

Pioneering microRNA solutions for the central nervous system

About

Spun out of Weizmann institute for Science in 2013, the company utilize RNA interference technology based on the robust scientific discoveries where a deep understanding of the biology behind microRNAs  involvement in central nervous system (CNS) related disorders, was gained.

Lead Program

Treatment resistant depression therapy. A novel RNA interference proprietary targeting key mRNAs involved in depression.
micurerx_Iconos_azul-04

Based in miR-135

which was demonstrated to act as a key modulator of depression and anxiety in numerous models

micurerx_Iconos_azul-02

Selective

No reduction of post-synaptic HTR1A

micurerx_Iconos_azul-03

Facilitates

Serotonin increase in the brain

micurerx_Iconos_azul-06

Technology

Non-invasive brain delivery

micurerx_Iconos_azul-01

Dual activity

Modulates both Serotonin transporter and serotonin auto receptor

micurerx_Iconos_azul-05

Precision medicine

With neuron targeting specifically in the dorsal raphe nucleolus

micurerx_Iconos_azul-07

High profile

Immunological safety

Technology

miCure owns a technology of a non-invasive brain delivery of oligonucleotides like siRNAs, miRNAs and ASOs that allows targeting gene expression modulation in specific cell types (pathology related population). The technology is based on linking the oligonucleotide of interest to a ligand of a neurotransmitter transporter and was demonstrated to be effective in NHP studies.

News

Phone

+34663885719

Email Address

info@micurerx.com

Address

Amot Investment Tower, 2 Weizmann St., 24th Floor Tel-Aviv 6423902 , Israel

Contact

Write Us and we'll get back to you